10 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
on treatment Investigational product safety profile remains clean after1,300 patients treated to date1 Phase 2 results support advancing to Phase 3
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
to within normal ranges. The safety profile for LUM-201 remained clean throughout both Phase 2 trials, with no safety concerns identified in either
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
the sustained effectiveness of AHV up to 24 months. Furthermore, the safety profile for LUM-201 remained clean throughout both Phase 2 studies, with no safety … a clean safety record, characterized by an absence of treatment-related Serious Adverse Events (SAEs), no instances of participants discontinuing
8-K
EX-99.2
oqf50cj
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-1.1
cr9eb
31 Jan 13
NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
12:00am
8-K
EX-10.2
vayz8t
18 Nov 11
Entry into a Material Definitive Agreement
12:00am
- Prev
- 1
- Next